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this may impair the virological response to an NVP-containing highly active antiretroviral therapy (HAART) regimen when maternal treatment is initiated [5] .
In Abidjan, Cote d'Ivoire, we have evaluated the combination of short-course ZDV plus lamivudine (3TC) and SD-NVP and could not demonstrate its superiority to ZDV plus SD-NVP for PMTCT [6] . We hypothesized, however, that by adding 3 days of ZDV plus 3TC postpartum we could reduce the period during which the mother is exposed to SD-NVP and, thus, could reduce the risk of NVP resistance. We here report on the occurrence of viral mutations with this regimen, to better inform PMTCT guidelines.
Subjects, materials, and methods. The Agence Nationale de Recherches sur Ie SIDA (ANRS) Ditrame Plus 1201.1 protocol was an open-label intervention study enrolling subjects between August 2002 and July 2003. Consenting HIV-I-infected pregnant women started oral ZDV and 3TC (300-mg and I50-mg tablets, respectively, twice a day) at~32 weeks of gestation. This antiretroviral regimen was completed by 2 tablets of ZDV (600 mg) and 3TC (300 mg) at the beginning of labor, together with SD-NVP (200-mg tablet). The ZDV plus 3TC maternal regimen was continued for 3 days postpartum. Infants received ZDV syrup (2 mg/kg/6 h) for 7 days, and SD-NVP (2 mg/kg) at day 2 postpartum.
In the present study, we included 16 of 17 transmitting mothers (1 died at day 20 postpartum) and 80 nontransmitting mothers, who were selected as a stratified random sample from the 275 nontransmitting mothers on the basis of baseline (before receipt of antiretroviral prophylaxis) maternal HIV-I RNA plasma viral load (RNA VL) and CD4+ T cell count distribution, as follows: 41 mothers with RNA VLs~4 log,o copies/mL and CD4+ T cell counts~500 cells/mm', 17 mothers with RNA VLs~4 log,o copies/mL and CD4+ T cell counts >500 cells/ mm 3 , 12 mothers with RNA VLs <4 log,o copies/mL and CD4+ T cell counts~500 cells/mm', and 10 mothers with RNA VLs <4 loglo copies/mL and CD4+ T cell counts >500 cells/mm 3 • 
-G.).
This study is dedicated to Pierrette Kassi, midwife and member of the ANRS Ditrame Plus Study Group, who died suddenly on 20 December 2004, while taking care of the patients in this study. The frequency of resistance mutations was estimated in the cohort of Agence Nationale de Recherches sur Ie SIDA Ditrame Plus, a study that evaluated the combination of shortcourse zidovudine (ZDV) plus lamivudine (3TC) and singledose nevirapine (SD-NVP) followed by 3 days of postpartum ZDV plus 3TC for the prevention of mother-to-child transmission of human immunodeficiency virus type 1 (HIV-l). The frequency with which resistance mutations were detected in mothers at week 4 postpartum was 1.14% (95% confidence interval [CI], 0.03%-6.17%) for NVP and 8.33% (95% CI, 3.66%-15.76%) for 3TC. In multivariate analysis, 3TC resistance was associated with a longer duration of ZDV plus 3TC prepartum prophylaxis (p::= .009). This regimen, which is feasible in resource-limited settings, prevents most peripartum HIV-l transmission and minimizes the development of NVP resistance.
Prevention of mother-to-child transmission of HIV-I (PMTCT) is a key component of the worldwide response to the pandemic and is based on the prophylactic use of antiretrovirals. World Health Organization (WHO) guidelines [1] recommend the use of PMTCT regimens, including single-dose nevirapine (SD-NVP) both alone and in conjunction with short-course zidovudine (ZDV). However, SD-NVP-containing regimens frequently induce NVP resistance mutations in women and infants [2] [3] [4] , and this may impair the virological response to an NVP-containing highly active antiretroviral therapy (HAART) regimen when maternal treatment is initiated [5] .
In the present study, we included 16 of 17 transmitting mothers (1 died at day 20 postpartum) and 80 nontransmitting mothers, who were selected as a stratified random sample from the 275 nontransmitting mothers on the basis of baseline (before receipt of antiretroviral prophylaxis) maternal HIV-I RNA plasma viral load (RNA VL) and CD4+ T cell count distribution, as follows: 41 mothers with RNA VLs~4 log,o copies/mL and CD4+ T cell counts~500 cells/mm', 17 mothers with RNA VLs~4 log,o copies/mL and CD4+ T cell counts >500 cells/ mm 3 , 12 mothers with RNA VLs <4 log,o copies/mL and CD4+ T cell counts~500 cells/mm', and 10 mothers with RNA VLs <4 loglo copies/mL and CD4+ T cell counts >500 cells/mm 3 • All of the mothers selected had started prepartum ZDV plus 3TC, but 8 of them (2 transmitting mothers and 6 nontransmitting mothers) did not receive SD-NVP and were excluded from the NVP resistance study. For the 96 women, plasma samples were tested at week 4 postpartum. For women whose plasma harbored virus with NVP and/or 3TC resistance mutations at this time point, prepartum plasma samples were tested to determine that the resistance mutations were not present before antiretroviral initiation. Plasma samples were available for HIV-1 genotyping for 16 of 17 infected infants. When NVP and/or 3TC resistance mutations were detected, maternal delivery samples were tested. RNA VL was measured using a real-time reverse-transcription polymerase chain reaction (PCR) technology [7] , with a threshold of 2.48 10glO copies/mL (300 copies/mL). HIV-1 genotyping was performed using the ANRS consensus technique [8] , and HIV-1 subtyping was performed by phylogenetic analysis of pol region sequences [9] .
Comparisons between groups were made using Student's t test or the Mann-Whitney U test for quantitative variables and the X 2 test or Fisher's exact test for qualitative variables. All factors potentially associated with NVP and 3TC resistance mutations were studied in univariate and then multivariate logistic regression analyses. In the crude and adjusted comparisons of the prevalence of NVP resistance mutations, published data on pregnant women from the same population who received shortcourse ZDV plus SD-NVP in the ANRS Ditrame Plus 1201.0 protocol, which enrolled subjects between March 2001 and July 2002 [3] , were used as a reference.
Results. The characteristics of the 96 mothers before receipt of antiretroviral prophylaxis are described in table 1. The median RNA VL and CD4+ T cell count of the nontransmitting mothers who were included in the resistance study were not statistically different from those who were not included. At a median of day 2 postpartum, 48 (51.6%) of the 93 women with available plasma samples had RNA VLs <2.48 10g]O copies/mL.
Of the 88 mothers who received short-course ZDV plus 3TC and SD-NVP, 1 (2239), a nontransmitting mother, had NVP resistance mutations (l03N/K and 181Y/C) detected at week 4 postpartum, giving a frequency of 1.14% (95% confidence interval [CI], 0.03%-6.17%)-much lower than the frequency of 33.3% (95% CI, 21.9%-41.3%) found in pregnant women from the same population in whom short-course ZDV plus SD-NVP was evaluated during the preceding period [3] (P< , for the unadjusted analysis; P < 10-3 , after adjustment for baseline RNA VL, CD4+ T cell count, and intake of repeated doses of NVP). Of the 96 women who received ZDV plus 3TC for a NOTE. Data are no (%) of women, unless otherwise noted. lOR, interquartile range; RNA VL, maternal HIV-l RNA plasma viral load.
a Transmitting mothers vs. nontransmitting mothers included in the resistance study. b Nontransmitting mothers included in the resistance study vs. nontransmitting mothers not included in the resistance study.
All of the mothers selected had started prepartum ZDV plus 3TC, but 8 of them (2 transmitting mothers and 6 nontransmitting mothers) did not receive SD-NVP and were excluded from the NVP resistance study. For the 96 women, plasma samples were tested at week 4 postpartum. For women whose plasma harbored virus with NVP and/or 3TC resistance mutations at this time point, prepartum plasma samples were tested to determine that the resistance mutations were not present before antiretroviral initiation. Plasma samples were available for HIV-1 genotyping for 16 of 17 infected infants. When NVP and/or 3TC resistance mutations were detected, maternal delivery samples were tested. RNA VL was measured using a real-time reverse-transcription polymerase chain reaction (PCR) technology [7] , with a threshold of 2.48 10glO copies/mL (300 copies/mL). HIV-1 genotyping was performed using the ANRS consensus technique [8] , and HIV-1 subtyping was performed by phylogenetic analysis of pol region sequences [9] .
Of the 88 mothers who received short-course ZDV plus 3TC and SD-NVP, 1 (2239), a nontransmitting mother, had NVP resistance mutations (l03N/K and 181Y/C) detected at week 4 postpartum, giving a frequency of 1.14% (95% confidence interval [CI], 0.03%-6.17%)-much lower than the frequency of 33.3% (95% CI, 21.9%-41.3%) found in pregnant women from the same population in whom short-course ZDV plus SD-NVP was evaluated during the preceding period [3] (P< , for the unadjusted analysis; P < 10- (table  2) . The woman in whom NVP resistance mutations were detected at week 4 postpartum also had a 3TC resistance mutation detected at week 4 postpartum. None of the 8 women who had 3TC resistance mutations detected at week 4 postpartum had detectable 3TC resistance mutations prepartum.
Baseline RNA VL and duration of ZDV plus 3TC prepartum prophylaxis were both significantly and positively associated with the presence of the 3TC 184V resistance mutation in univariate analysis (P = .05 and P = .02, respectively), whereas the other factors investigated-maternal age, WHO clinical stage, CD4+ T cell count, and HAART eligibility criteria-were not (P> .20, for all variables). In multivariate analysis, duration of ZDV plus 3TC prepartum prophylaxis was the only risk factor for the presence of the 3TC 184V resistance mutation at week 4 postpartum (P = .009). Of the 17 infected infants, 1 died at day 22, and the remaining 16 were included in the resistance study. For 2 of them, the mother did not take SD-NVP at delivery. The NVP 101E and 3TC 184V resistance mutations were detected in 1 infant at week 4 oflife, and only the 3TC 184V resistance mutation was detected in another 3 infants at week 4 of life. The patterns of resistance mutations detected in mothers and infants were different (table 2) . No mutations were detected in the maternal plasma samples collected at delivery and at week 4 postpartum for the mother of the infant (2175) in whom the NVP 101E and 3TC 184V resistance mutations were detected at week 4 postpartum. For 2 of the infants (1502 and 2145) who had only the 3TC 184V resistance mutation detected at week 4 postpartum, no mutations were detected in both of their mothers at week 4 postpartum and in 1 of their mothers at delivery. For the other infant (1615) who had only the 3TC 184V resistance mutation detected at week 4 postpartum, the 3TC 184V mutation was also detected in the mother at both day 2 and week 4 postpartum (table 2) .
Of the 16 infected infants,S died at a median age of 98 days (range, 67-206 days) before HAART could be initiated, and the 11 others initiated HAART at a median age of 7 months (range, 4-14 months). In the 3 infants in whom only the 3TC (1502), from 14.8% to 29.2% after 15 months of treatment (2145), and from 14.7% to 27.2% after 5 months of treatment (2175). For the infant (1615) in whom both the NVP 101E and 3TC 184V resistance mutations were detected at week 4 postpartum, the CD4+ T cell percentage increased from 22.5% to 33.8% after 14 months of treatment.
Phylogenetic analysis of the 96 HIV-1 maternal strains revealed that 75% were CRF02, 17% were subtype A, 4% were CRF06, and 1% was subtype G; 3% were undetermined. The virus harbored by each given mother clustered with the virus harbored by her infant.
Discussion. The addition of 3 days of postpartum ZDV plus 3TC to prepartum short-course ZDV plus 3TC and SD-NVP produced a low rate of development of NVP resistance mutations and a high PMTCT efficacy. This antiretroviral regimen yielded one of the lowest peripartum MTCT rates ever published for a short-course prophylactic regimen in Africa. Moreover, it dramatically reduced the rate of the development of NVP resistance mutations in mothers (1.14%) and infected infants. In previous studies in Uganda, South Africa, Cote d'Ivoire, and Thailand, the frequency of these mutations in women receiving SD-NVP with or without short-course ZDV has ranged from 19% to 40% [2] [3] [4] 10] . The comparison we performed with results obtained in pregnant women from the same population who had received short-course ZDV plus SD-NVP [3] must be considered exploratory, given the observational nature of the data. In the PACTG 316 trial, in which 76% of the participating pregnant women received combination therapy in addition to SD-NVP, NVP resistance mutations were observed in 15% of the mothers [11] . High prepartum RNA VLs, low CD4+ T cell counts, and high NVP concentrations at delivery have been associated with the development of mutations [3, 4, 12] . Moreover, differences in resistance according to HIV-1 subtypes have also been reported [13] . In the present study, by systematically including transmitting mothers and a sample of nontransmitting mothers on the basis of RNA VL and CD4+ T cell count distribution, we overrepresented women with low CD4+ T cell counts and high RNA VLs, thus possibly overestimating the overall frequency ofNVP resistance mutations in the study population-although the upper 95% CI was only 6.17%. On the other hand, recent studies have demonstrated that more-sensitive techniques, such as allelespecific PCR, can reveal rates ofNVP resistance mutations that are higher than those reported when standard genotyping is used [14] .
The long half-life ofNVP is more likely to induce a prolonged viral replication under suboptimal drug-selective pressure, therefore increasing the probability of emergence of resistant strains. In the present study, the addition of 3TC to shortmedian duration of 51 days (interquartile range [IQR], 34-63 days), 8 (8.33% [95% CI, 3.66%-15.76%]) had the 184V mutation for 3TC resistance detected at week 4 postpartum (table 2). The woman in whom NVP resistance mutations were detected at week 4 postpartum also had a 3TC resistance mutation detected at week 4 postpartum. None of the 8 women who had 3TC resistance mutations detected at week 4 postpartum had detectable 3TC resistance mutations prepartum.
Of the 16 infected infants,S died at a median age of 98 days (range, 67-206 days) before HAART could be initiated, and the 11 others initiated HAART at a median age of 7 months (range, 4-14 months). In the 3 infants in whom only the 3TC 184V resistance mutation was detected at week 4 postpartum, the CD4+ T cell percentage increased from 18.3% to 37% after 21 months of treatment (1502), from 14.8% to 29.2% after 15 months of treatment (2145), and from 14.7% to 27.2% after 5 months of treatment (2175). For the infant (1615) in whom both the NVP 101E and 3TC 184V resistance mutations were detected at week 4 postpartum, the CD4+ T cell percentage increased from 22.5% to 33.8% after 14 months of treatment.
The long half-life ofNVP is more likely to induce a prolonged viral replication under suboptimal drug-selective pressure, therefore increasing the probability of emergence of resistant strains. In the present study, the addition of 3TC to short- course ZDV during pregnancy, together with SD-NVP, led to a tight control of viral replication in more than half of the mothers at delivery (i.e., at the time when the highest NVP levels were reached). Providing additional postpartum antiretroviral exposure with ZDV plus 3TC immediately after SD-NVP extended the suppression of viral replication while plasma NVP levels were detectable. NVP or 3TC resistance mutations are also a concern for the infants who become infected despite receipt of prophylaxis. In previous studies, detectable NVP resistance mutations have been found in 23%-46% of plasma samples from infected infants exposed to SD-NVP, either alone [4] or after short-course ZDV [3] . Our results suggest different mechanisms of acquisition of drug resistance in infants. NVP-resistant virus might have been selected as the infant received SD-NVP, and no mutation was found in maternal plasma. For 3TC, the resistant virus was probably transmitted from the mother in 1 case, whereas, in the 2 remaining cases, the 3TC mutation could have been selected in the infant or transmitted by breastfeeding.
From a treatment perspective, a study in Thailand has raised concerns that the response to HAART could be impaired in women exposed to SD-NVP [5] . The clinical implications of these findings remain uncertain, because this association held only for the 6-month virological response. Although we have described a limited case series, we did not find early evidence of impaired immunological response to treatment, either in women or in infants.
The emergence of ZDV resistance mutations is not an issue for PMTCT [1] , as was confirmed in the present study. Conversely, the emergence of 3TC resistance mutations and, even more, of NVP resistance mutations is a serious and growing concern. The impact of the 3TC 184V resistance mutation on subsequent response to 3TC-containing HAART regimens is, at present, unknown. The preliminary results of a randomized controlled trial in South Africa [15] showed that, in mothers who received only SD-NVP, 60% of virus was resistant, compared with 10%-12% when 4 or 7 days of postpartum ZDV plus 3TC was added. The regimen we evaluated is longer and more complex, although it is, nonetheless, a short-course PMTCT regimen. It yielded one of the lowest MTCT rates ever reported in Africa, with low NVP and 3TC resistance detected by standard methods. Thus, it induces less concern with respect to maternal and pediatric responses to HAART. The risk-reward elements of the recommended PMTCT interventions in resource-limited settings need to be revisited, especially for those pregnant women who do not require receipt of HAART or who do not have access to it [1] , given that linking PMTCT and care is of utmost priority.
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